Palatin Technologies (PTN) Share-based Compensation (2010 - 2026)
Palatin Technologies' (PTN) quarterly Share-based Compensation came in at $419968.0 in Q1 2026, up 20.79% YoY from $347691.0 in Q1 2025, and up 35.15% on a QoQ basis from $310739.0 in Q4 2025.
Palatin Technologies (PTN) Share-based Compensation (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 17 years of Share-based Compensation data on file, last reported at $419968.0 in Q1 2026.
- Quarterly Share-based Compensation rose 20.79% year-over-year to $419968.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$215480.0 (down 120.61% YoY) and the FY2025 annual result came in at $99482.0, up 76.38% from the prior year.
- Share-based Compensation rose to $419968.0 in Q1 2026, from $310739.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $715591.0 in Q2 2022 to a low of -$946187.0 in Q2 2025.
- A 5-year average of $256307.0 and a median of $393546.5 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation plunged 322.78% — and 2025, when it surged 139.34%.
- Tracing PTN's Share-based Compensation over 5 years: stood at $618704.0 in 2022, then retreated by 11.11% to $549971.0 in 2023, then tumbled by 36.55% to $348955.0 in 2024, then slipped by 10.95% to $310739.0 in 2025, then jumped by 35.15% to $419968.0 in 2026.
- The last three Share-based Compensation figures came in at $419968.0 (Q1 2026), $310739.0 (Q4 2025), and -$946187.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Palatin Technologies | 40.86 Mn | 40.86 Mn | - | 419,968.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 419,968.00 |
| Mar 31, 2026 | 419,968.00 |
| Dec 31, 2025 | 310,739.00 |
| Dec 31, 2025 | 310,739.00 |
| Jun 30, 2025 | -946,187.00 |
| Jun 30, 2025 | -946,187.00 |
| Mar 31, 2025 | 347,691.00 |
| Mar 31, 2025 | 347,691.00 |
| Dec 31, 2024 | 348,955.00 |
| Dec 31, 2024 | 348,955.00 |
| Sep 30, 2024 | 349,023.00 |
| Sep 30, 2024 | 349,023.00 |
| Mar 31, 2024 | -883,906.00 |
| Mar 31, 2024 | -883,906.00 |
| Dec 31, 2023 | 549,971.00 |
| Dec 31, 2023 | 549,971.00 |
| Sep 30, 2023 | 390,336.00 |
| Sep 30, 2023 | 390,336.00 |
| Mar 31, 2023 | 396,757.00 |
| Mar 31, 2023 | 396,757.00 |